long intergenic non-protein coding RNA 1395Genealiases: []
Q-omics provides the consensus-scored LINC01395 profile across patient tissues and cancer cell-line models. LINC01395 expression is associated with patient survival in 11 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, LINC01395 is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, LINC01395 RNA expression shows 7,291 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight HNSC, and ESCA as cancer lineages where LINC01395 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01395 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01395 survival associations across molecular data types. LINC01395 RNA expression shows survival associations in the most cancer types (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01395 RNA expression–survival associations across cancer types. High LINC01395 expression shows unfavorable associations in MESO, DLBC and THCA, but favorable associations in HNSC, LUAD and CHOL. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify HNSC as the clearest survival context for LINC01395 RNA expression.
This table summarizes LINC01395 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01395. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01395 shows lower tumor expression in HNSC, BRCA and KIRP and higher tumor expression in LUAD, LUSC and LIHC. The HNSC box plot shows higher LINC01395 RNA expression in normal versus tumor tissue (log2 FC = −1.862, t-test p < 0.001).
This table shows molecular features associated with LINC01395 in patient tissues and cancer cell lines. In patient samples, LINC01395 shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set.
